Teriparatide as a systemic treatment for lower extremity nonunion fractures: A case series

Edna E. Mancilla, Jill L. Brodsky, Samir Mehta, Robert J. Pignolo, Michael A. Levine

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the effect of teriparatide (parathyroid hormone [1-34]) on the healing of long bone nonunion fractures.Methods: We performed a retrospective chart review of patients with fracture nonunion, aged 10 to 99 years who were treated with teriparatide at the Children's Hospital of Philadelphia or the Hospital of the University of Pennsylvania between November 2002 and January 2013. The primary endpoints were radiographic evidence of callus formation and fracture union, ability to bear weight without affected limb limp, and normal range of motion and strength.Results: Six patients aged 19 to 64 years with tibial or femoral fractures that had not healed for 3 to 36 months were treated with teriparatide 20 μg/day. Accelerated healing of fracture nonunion was confirmed in 5 of 6 patients with time to complete union of 3 to 9 months. The shortest time to recovery was observed in younger patients without comorbidities. Treatment was well tolerated.Conclusion: Teriparatide is a promising treatment for nonunion fractures, but its response depends on associated comorbidities. The potential benefit of teriparatide as an adjunct to treat nonunion justifies randomized placebo-controlled trials to determine its efficacy and safety in broader populations.

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalEndocrine Practice
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Teriparatide
Lower Extremity
Comorbidity
Therapeutics
Tibial Fractures
Fracture Healing
Femoral Fractures
Bone Fractures
Bony Callus
Articular Range of Motion
Parathyroid Hormone
Reference Values
Extremities
Randomized Controlled Trials
Placebos
Safety
Weights and Measures
Population

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Mancilla, E. E., Brodsky, J. L., Mehta, S., Pignolo, R. J., & Levine, M. A. (2015). Teriparatide as a systemic treatment for lower extremity nonunion fractures: A case series. Endocrine Practice, 21(2), 136-142. https://doi.org/10.4158/EP14315.OR

Teriparatide as a systemic treatment for lower extremity nonunion fractures : A case series. / Mancilla, Edna E.; Brodsky, Jill L.; Mehta, Samir; Pignolo, Robert J.; Levine, Michael A.

In: Endocrine Practice, Vol. 21, No. 2, 01.02.2015, p. 136-142.

Research output: Contribution to journalArticle

Mancilla, EE, Brodsky, JL, Mehta, S, Pignolo, RJ & Levine, MA 2015, 'Teriparatide as a systemic treatment for lower extremity nonunion fractures: A case series', Endocrine Practice, vol. 21, no. 2, pp. 136-142. https://doi.org/10.4158/EP14315.OR
Mancilla, Edna E. ; Brodsky, Jill L. ; Mehta, Samir ; Pignolo, Robert J. ; Levine, Michael A. / Teriparatide as a systemic treatment for lower extremity nonunion fractures : A case series. In: Endocrine Practice. 2015 ; Vol. 21, No. 2. pp. 136-142.
@article{adb47c838b224970b9420b16015c4a2e,
title = "Teriparatide as a systemic treatment for lower extremity nonunion fractures: A case series",
abstract = "Objective: To investigate the effect of teriparatide (parathyroid hormone [1-34]) on the healing of long bone nonunion fractures.Methods: We performed a retrospective chart review of patients with fracture nonunion, aged 10 to 99 years who were treated with teriparatide at the Children's Hospital of Philadelphia or the Hospital of the University of Pennsylvania between November 2002 and January 2013. The primary endpoints were radiographic evidence of callus formation and fracture union, ability to bear weight without affected limb limp, and normal range of motion and strength.Results: Six patients aged 19 to 64 years with tibial or femoral fractures that had not healed for 3 to 36 months were treated with teriparatide 20 μg/day. Accelerated healing of fracture nonunion was confirmed in 5 of 6 patients with time to complete union of 3 to 9 months. The shortest time to recovery was observed in younger patients without comorbidities. Treatment was well tolerated.Conclusion: Teriparatide is a promising treatment for nonunion fractures, but its response depends on associated comorbidities. The potential benefit of teriparatide as an adjunct to treat nonunion justifies randomized placebo-controlled trials to determine its efficacy and safety in broader populations.",
author = "Mancilla, {Edna E.} and Brodsky, {Jill L.} and Samir Mehta and Pignolo, {Robert J.} and Levine, {Michael A.}",
year = "2015",
month = "2",
day = "1",
doi = "10.4158/EP14315.OR",
language = "English (US)",
volume = "21",
pages = "136--142",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "2",

}

TY - JOUR

T1 - Teriparatide as a systemic treatment for lower extremity nonunion fractures

T2 - A case series

AU - Mancilla, Edna E.

AU - Brodsky, Jill L.

AU - Mehta, Samir

AU - Pignolo, Robert J.

AU - Levine, Michael A.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective: To investigate the effect of teriparatide (parathyroid hormone [1-34]) on the healing of long bone nonunion fractures.Methods: We performed a retrospective chart review of patients with fracture nonunion, aged 10 to 99 years who were treated with teriparatide at the Children's Hospital of Philadelphia or the Hospital of the University of Pennsylvania between November 2002 and January 2013. The primary endpoints were radiographic evidence of callus formation and fracture union, ability to bear weight without affected limb limp, and normal range of motion and strength.Results: Six patients aged 19 to 64 years with tibial or femoral fractures that had not healed for 3 to 36 months were treated with teriparatide 20 μg/day. Accelerated healing of fracture nonunion was confirmed in 5 of 6 patients with time to complete union of 3 to 9 months. The shortest time to recovery was observed in younger patients without comorbidities. Treatment was well tolerated.Conclusion: Teriparatide is a promising treatment for nonunion fractures, but its response depends on associated comorbidities. The potential benefit of teriparatide as an adjunct to treat nonunion justifies randomized placebo-controlled trials to determine its efficacy and safety in broader populations.

AB - Objective: To investigate the effect of teriparatide (parathyroid hormone [1-34]) on the healing of long bone nonunion fractures.Methods: We performed a retrospective chart review of patients with fracture nonunion, aged 10 to 99 years who were treated with teriparatide at the Children's Hospital of Philadelphia or the Hospital of the University of Pennsylvania between November 2002 and January 2013. The primary endpoints were radiographic evidence of callus formation and fracture union, ability to bear weight without affected limb limp, and normal range of motion and strength.Results: Six patients aged 19 to 64 years with tibial or femoral fractures that had not healed for 3 to 36 months were treated with teriparatide 20 μg/day. Accelerated healing of fracture nonunion was confirmed in 5 of 6 patients with time to complete union of 3 to 9 months. The shortest time to recovery was observed in younger patients without comorbidities. Treatment was well tolerated.Conclusion: Teriparatide is a promising treatment for nonunion fractures, but its response depends on associated comorbidities. The potential benefit of teriparatide as an adjunct to treat nonunion justifies randomized placebo-controlled trials to determine its efficacy and safety in broader populations.

UR - http://www.scopus.com/inward/record.url?scp=84923420032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923420032&partnerID=8YFLogxK

U2 - 10.4158/EP14315.OR

DO - 10.4158/EP14315.OR

M3 - Article

C2 - 25297667

AN - SCOPUS:84923420032

VL - 21

SP - 136

EP - 142

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 2

ER -